Source:http://linkedlifedata.com/resource/pubmed/id/17511802
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2008-1-14
|
| pubmed:abstractText |
For women diagnosed with ovarian cancer, the standard practice of surgery followed by adjuvant platinum-taxane combination chemotherapy, with cycles administered every 3 weeks, is based on randomized control trials. However, a substantial number of patients require delays or reductions on this schedule. The Cancer Centre of Southeastern Ontario (CCSEO) has historically administered chemotherapy every 4 weeks. We analyzed survival outcomes of our cohort. All ovarian cancer patients treated with chemotherapy at the CCSEO from 1995 to end-2002 were included in this study. Overall survival and progression-free survival were calculated from initiation of chemotherapy using the Kaplan-Meier technique and log-rank tests. Cox regression analysis was used to adjust for age and disease stage. A total of 171 patients were treated with chemotherapy (cisplatin-paclitaxel or carboplatin-paclitaxel), of which 144 received chemotherapy every 4 weeks and 27 every 3 weeks. Median progression-free survival was 19.2 months for the group treated every 4 weeks vs 13.2 months for the 3-weekly group. Median overall survival was 36.5 months compared to 27.1 months, respectively. Trends favored treatment every 4 weeks. In early-stage disease, 5-year overall survival was 74% and 5-year progression-free survival was 68%. Administration of platinum-paclitaxel chemotherapy every 4 weeks did not reduce survival of ovarian cancer patients. Importantly, median survival is favorable compared to results from landmark trials where patients were treated every 3 weeks. These results suggest that decreasing the frequency of chemotherapy cycles does not decrease survival. Prospective trials would be required to compare quality of life and cost-effectiveness.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1525-1438
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
8-13
|
| pubmed:meshHeading |
pubmed-meshheading:17511802-Adenocarcinoma, Clear Cell,
pubmed-meshheading:17511802-Adenocarcinoma, Mucinous,
pubmed-meshheading:17511802-Aged,
pubmed-meshheading:17511802-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17511802-Carboplatin,
pubmed-meshheading:17511802-Carcinoma, Endometrioid,
pubmed-meshheading:17511802-Carcinoma, Papillary,
pubmed-meshheading:17511802-Cisplatin,
pubmed-meshheading:17511802-Cohort Studies,
pubmed-meshheading:17511802-Cystadenocarcinoma, Serous,
pubmed-meshheading:17511802-Disease-Free Survival,
pubmed-meshheading:17511802-Female,
pubmed-meshheading:17511802-Humans,
pubmed-meshheading:17511802-Middle Aged,
pubmed-meshheading:17511802-Neoplasm Staging,
pubmed-meshheading:17511802-Ovarian Neoplasms,
pubmed-meshheading:17511802-Paclitaxel,
pubmed-meshheading:17511802-Retrospective Studies,
pubmed-meshheading:17511802-Survival Rate,
pubmed-meshheading:17511802-Treatment Outcome
|
| pubmed:articleTitle |
Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
|
| pubmed:affiliation |
Department of Oncology and Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada.
|
| pubmed:publicationType |
Journal Article
|